Vitiligo

Below is a list of our vitiligo studies that are currently enrolling.

Phase III Vitiligo Study

Population: Participants aged 12 years or older
Study Condition: Stable or active vitiligo diagnosed for at least three months
Study Design: This is a double arm, open label, 20-week Phase III study with three and six-month follow up periods, in patients with a documented history of generalized vitiligo. Up to 200 eligible patients across study sites will be enrolled and randomised in equal numbers to one of the following treatment groups:
- Group A will receive NB-UVB twice weekly from Day 0 (40 treatments in total), and SCENESSE® (one implant administered on Days 0, 21 (±4), 42 (±4), 63 (±4), 84 (±4), 105(±4) and 126 (±4) (seven implants in total));
To determine eligibility for study participation, patients will undergo a screening evaluation within a 28-day period before receiving the first study treatment.
Duration: Approximately 12 months
Compensation may be provided for participation.

Group B will receive NB-UVB light only (administered twice weekly for 20 weeks, 40 treatments in total).

Please contact Courtney Rowley for more information regarding ongoing vitiligo studies.